Nature: Scientists in China have discovered that the new coronary virus S-RBD vaccine induces a protective immune response.

6, 2020 /--- -- The new coronavirus SARS-CoV-2, which causes coronavirus disease (COVID-19) in 2019, is now spreading around the world.
urgent need for an effective preventive vaccine against the virus.
however, there is currently no human vaccine for SARS-CoV-2, but about 120 candidate vaccines are being developed.
SARS-CoV-2 is associated with two other highly pathogenic viruses, SARS-CoV and MERS-CoV.
SARS-CoV-2 has a just, single-stranded RNA genome of 30kb in size.
its outer membrane, which consists of a nuclear crust protein (N) and a membrane protein (M), enclosure protein (E), and a tingling protein (S) encloses its genome.
Like SARS-CoV, SARS-CoV-2's S proteins bind to their common receptacle angiotensin conversion enzyme 2 (ACE2) through the receptacle binding domain (RBD) to mediat the virus into the host cell.
S protein contains two functional sub-sub-sub-s1s and S2, where S1 is responsible for binding to the host cell receptacle and S2 sub-sub-sub-cells are responsible for viral membrane and cell membrane fusion.
,S(TMPRSS2)NS1CS2,。
S1 and S2 are composed of extracellous domain (ECD) and a single trans-membrane helix, respectively, mediated recepor binding and membrane fusion.
S1 consists of an N-side domain (NTD) and a receptor-combined domain (RBD), which is critical to determining the organization's addiction and hosting range.
picture Source: .
Prior to this, scientists had confirmed that RBDs from SARS-CoV and MERS-CoV contained major image-dependent neutralized etibodies and were capable of producing powerful neutralized antibodies in immune animals, thus promising targets for vaccine development.
In a new study, researchers from research institutions such as Sichuan University of China, Macau University of Science and Technology, and Beijing Concord Medical College constructed a recombinant vaccine (S-RBD) amino acid residue 319-545 consisting of S protein binding domain (RBD) residues, and found that effective functional antibody reactions were exported within 7 or 14 days of the injection of this recombinant vaccine in mice, rabbits, and non-human primate rhesus monkeys.
the findings were published online July 29, 2020 in the journal Nature, entitled "A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces the immunity".
serum from these vaccinated animals blocks the binding of RBD to ACE2 expressed on the cell surface, and in in-body energy and infection with SARS-CoV-2 prosthetic and SARS-CoV-2 live viruses.
importantly, in vivo, this recombinant vaccine also protects non-human primates from SARS-CoV-2 attacks.
also found elevated levels of RBD-specific antibodies in the serum of COVID-19 patients.
several immune pathways and CD4-T cells were involved in the antibody response induced by this recombinant vaccine.
these findings highlight the importance of RBD domains in SARS-CoV-2 vaccine design and provide a theoretical basis for the development of protective vaccines that induce antibody production for RBD domains.
(bioon.com) Reference: Jingyun Yang et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces the immunity. Nature, 2020, doi:10.1038/s41586-020-2599-8.